ASSOCIATOIN OF CHINESE AMERICANS IN CANCER RESEARCH

Association of Chinese Americans in Cancer Research

Newsletter

Newsletter October 2024

Inside this issue:

President's welcome message

Dear ACACR members and friends,

It is truly my great honor to serve as ACACR President for the term of 2023-2024. During the past two years, I have had the pleasure working with Dr. Erxi Wu as General Secretary and Dr. Lanjing Zhang as Treasurer, as well as Drs. Shiyuan Cheng, Zhenkun Lou, Lin Zhang as the council members. I want to thank each of this team for their great contributions and service to the society.

On April 15, 2023, we held our annual meeting in Orlando, Florida. Over 180 people attended the meeting. Keynote speakers included Dr. Ray Huang, Founder and CEO of RayBiotech Group, Dr. Chak Sing Lau, Dean of the Faculty of Medicine at the University of Hong Kong, and Dr. Dihua Yu, Chair at MD Anderson Cancer Center.

The following year, on April 6, 2024, we had the annual meeting on the UCSD Medical School campus. At this meeting, we had Dr. Tony Hunter, a world-renowned cancer researcher and pioneer of tyrosine phosphorylation and signal transduction presented a keynote speech. Of note, the society established the "Tony Hunter Cancer Research Award", which will recognize one senior and one junior cancer researcher every year. Dr. Lieping Chen, professor at Yale University, was chosen as the first senior recipient of "Tony Hunter Cancer Research Award", for his pioneering work in cancer immunotherapy. The junior award recipient was Dr. Peiwen Chen, assistant professor at Northwestern University, for his contribution to the studies on the molecular and biological processes governing the development of primary and metastatic brain cancers. A big THANKS to Dr. Shiyuan Cheng who served as the first chair and Boyi Gan, Zhenkun Lou, Erxi Wu, Wei Xu, Jing Yang, Lanjing Zhang, Lin Zhang as members of the Tony Hunter Award committee.

Our collaborations with the US Chinese Anti-Cancer Association (USCACA) and the leadership of Dr. Shi-Yong Sun for the USCACA have been instrumental in the success of both annual meetings.

We have had very successful Summer virtual meetings in 2023 and 2024. We have been very fortunate to have many outstanding senior and junior researchers present very interesting data and stories in the broad areas of cancer research. This virtual seminar series will be continued in the future years, which allows ACACR members to learn great science and cutting-edge technologies.

Given that the annual meeting of ACACR will be held in April each year, in association with the AACR meeting, we have decided to make the transition of administration on July 1, every other year. From July 1, 2024, Dr. Boyi Gan is the president, till June 30, 2026. Thank you, Boyi, for the willingness to serve. This transition time will allow the new president sufficient time to prepare and organize our annual meetings. Again, it is indeed a rewarding experience to serve for ACACR.

Gen-Sheng Feng, PhD

President, ACACR (2023-2024)
Professor, University of California San Diego, San Diego, CA.

Current President's welcome message

Dear ACACR members and friends,

It is with great honor and privilege that I assume the role of President of the Association of Chinese American in Cancer Research (ACACR). Our organization has flourished under the outstanding leadership of my esteemed predecessors—Drs. Shi-Yuan Cheng, Zhenkun Lou, Lin Zhang, and Gen-Sheng Feng—and I am both excited and humbled to carry forward their legacy. Their leadership has paved the way for ACACR's growth, and I am committed to building upon their accomplishments to serve our vibrant community even better.

Over the past several years, ACACR has experienced remarkable growth. Our association has become a hub of collaboration, innovation, and knowledge sharing, fostering an environment where ideas flourish, and meaningful connections are made. The strength of ACACR lies in its members—a dynamic and diverse group of scientists, researchers, clinicians, and industry professionals, all united in a shared commitment to combat cancer. It is my goal to not only preserve this strong sense of community but also to cultivate new opportunities for interaction and collaboration that can drive significant advancements in cancer research.

Looking ahead, I am particularly enthusiastic about expanding the scope of collaboration within our association. One of my key priorities will be to foster interdisciplinary partnerships and support the professional growth of our members, from early-career researchers to senior investigators. ACACR's annual meeting, held during the AACR Annual Meeting, will continue to be a cornerstone of our organization, bringing together colleagues and friends to exchange ideas, share breakthroughs, and inspire new collaborations.

I am also proud of the success of the ACACR Virtual Seminar Series, which we launched during the pandemic and has been very well received by our community. The series has provided an invaluable platform for knowledge exchange, particularly during challenging times when in-person interactions were limited. We will continue this initiative, providing a space where members can engage with cutting-edge research and network with colleagues. I am especially delighted by the participation of our junior faculty in these seminars, whose presentations have been outstanding. In the future, we will continue to highlight the work of junior PIs, showcasing their contributions and supporting the next generation of cancer researchers.

More than just an association, ACACR is a family—a community that lifts each other up, working together toward common goals. As we move forward, I am confident that we will continue to make meaningful and impactful strides in the field of cancer research. Together, we will push the boundaries of science, uncover new therapeutic strategies, and ultimately improve the lives of cancer patients.

Thank you for your unwavering dedication to this community and to the mission we all share. I look forward to working closely with each of you as we embark on this exciting journey together.

Warmest regards,

Boyi Gan, Ph.D.

President, Association of Chinese American in Cancer Research (ACACR), 2024-2026

N.G. and Hellen T. Hawkins Distinguished Professor for Cancer Research

Department of Experimental Radiation Oncology

The University of Texas MD Anderson Cancer Center

2024 Annual Meeting (see also online)

When: 1:30 – 7:00 pm, Saturday, April 06, 2024

Where: MET Lower Auditorium, T. Denny Sanford Medical Education and Telemedicine Center, University of California San Diego, 9500 Gilman Dr, La Jolla, CA

Agenda

2:00 - 2:10 Welcome messages by Dr. Gen-Sheng Feng (ACACR President, UCSD)
and Dr. Shi-Yong Sun (USCACA President, Emory University)
2:10 – 3:05 ACACR Award Session, Chaired by Dr. Gen-Sheng Feng, UCSD
2:15 – 2:20 Announcement of 2024 Winners of Tony Hunter Award in Cancer Research
by Award Committee Chair, Dr. Shi-Yuan Cheng, Northwestern University
2:20 – 2:25 Presentation to the Inaugural Award to Senior Investigator and Junior
Investigator by Dr. Tony Hunter
2:25 – 2:45 Dr. Lieping Chen, Yale University, Tony Hunter Award Winner (Senior
Investigator Awardee), Introduced by Dr. Wei Xu, Univ of Wisconsin,
Madison. Title: "Cancer immunotherapy: what have we learnt and what is next?"
2:45 – 3:05 Dr. Peiwen Chen, Northwest University, Tony Hunter Award Winner (Junior
Investigator Awardee), Introduced by Dr. Shi-yuan Cheng, Northwestern U
Title: "Targeting tumor-macrophage/microglia symbiosis in glioblastoma"
3:05 – 3:25 USCACA Award Session, Dr. Shi-Yong Sun, Emory University
USCACA Outstanding Young Chinese Scholar Awards Announcement and
Presentations (Dr. Xuefeng Liu, The Ohio State University)
3:25 – 3:35 Business meeting of the two societies
Update on ACACR Publication/Newsletters: Dr. Zhenghe Wang, Case
Western Reserve University
3:35 – 3:55 Coffee break (Group Photo)
3:55 – 4:45 Keynote address, Dr. Tony Hunter, Salk Institute of Biological Sciences
Introduced by Dr. Jing Yang, UCSD. Title: "Tyrosine Phosphorylation and Cancer"
4:45 – 5:10 Sponsors' presentations, chaired by ACACR General Secretary, Dr. Erxi
Wu, Baylor College of Medicine
5:10 – 5:15 Concluding remarks, Dr. Boyi Gan, ACACR President-elect
5:15 – 7:00 Networking/Buffet Dinner

Organizing committee (alphabetical order):

Shiyuan Cheng, PhD; Gen-Sheng Feng, PhD; Boyi Gan, PhD, Zhenkun Lou, PhD; Erxi Wu, PhD; Wei Xu, PhD; Jing Yang, PhD; Lanjing Zhang, MD; Lin Zhang, PhD

Dr Gen-Sheng Feng, ACACR President (2023-2024)

Dr Boyi Gan, ACACR current President

Dr Shi-Yong Sun, USCACA President

Drs Gen-Sheng Feng and Shi-Yong Sun

Dr Tony Hunter, ACACR Keynote Speaker

Dr Lieping Chen, ACACR Keynote Speaker



Drs, Tony Hunter, Lieping Chen, Shiyuan Cheng,& Gen-Sheng Feng

Drs, Tony Hunter, Peiwen Chen,& Shiyuan Cheng

Audience

Audience

All attendees

Photo credits
Drs. Dan Qi, Emily Wang and Erxi Wu

Members' Research Highlights

Dr. Peiwen Chen at Northwestern University and now at Cleveland Clinic discovered the role and underlying mechanisms of context-dependent cell-to-cell interactions in glioblastoma (GBM), which include

1) TFPI2-mediated interaction between glioblastoma stem cells (GSCs) and microglia in GBM progression and immunosuppression (***Nature Immunology*** 2023, Cover article, https://pubmed.ncbi.nlm.nih.gov/37667051/);

2) CLOCK-mediated GSC-endothelial cell interaction in GBM angiogenesis (***Cell Reports*** 2023, https://pubmed.ncbi.nlm.nih.gov/36795563/);

3) Hypoxia-mediated macrophage-T cell interaction in GBM immunosuppression (***Cell Reports Medicine*** 2023, https://pubmed.ncbi.nlm.nih.gov/37858339/);

4) glycolysis-mediated tumor-macrophage interaction in GBM progression (***Nature Communication*** 2024, https://pubmed.ncbi.nlm.nih.gov/37886538/); and

5) *PTEN* deficiency-mediated macrophage-microglia interaction in GBM progression and immunosuppression (***Journal of Clinical Investigation*** 2024, https://pubmed.ncbi.nlm.nih.gov/39352749/).

Dr. Zhenghe John Wang at Case Western Reserve University discovered that neutrophil extracellular traps (NETs) induced by chemotherapy inhibit in vivo tumor growth. Increased levels of NETs post-chemo treatment are associated with longer progression-free survival in patients. This article is published in the ***Journal of Clinical Investigation***: https://www.jci.org/articles/view/175031. Dr. Zhenghe John Wang became the chairman of the Department of Genetics and Genome Sciences at the School of Medicine, Case Western Reserve University, on July 1, 2023.

Dr. Wei Xu at the University of Wisconsin-Madison generated a novel model that recapitulates blastemal Wilms Tumors (WTs), enabling the discovery of therapeutic vulnerability for high-risk WTs. Screening of FDA-approved drugs in WiT49 and reprogrammed WiT49 cells identifies epithelial- or blastemal-dominant WT-sensitive drugs. This study was published in *Cell Reports Medicine* in 2024 (https://pubmed.ncbi.nlm.nih.gov/39368485/)

Dr. Qing Zhang at the University of Texas Southwestern Medical Center (UTSW) recently identified DCLK2 as a bona fide kinase for activating TBK1 signaling in kidney cancer. This article was published in **Mol Cell** in 2024 (https://pubmed.ncbi.nlm.nih.gov/38211588/). In another study, his lab also discovered that von hippel lindau (VHL) tumor suppressor controls m6A-dependent gene expression in renal tumorigenesis, which was published in ***Journal of Clinical Investigation*** in 2024 (https://pubmed.ncbi.nlm.nih.gov/38618952/). In 2024, Dr. Zhang also recently received the young investigator award from Chinese Biomedical Investigator Society (CBIS) and outstanding investigator award from American Society of Investigative Pathology (ASIP). He recently was appointed as the director of investigative pathology in the Department of Pathology at UTSW and assumed the duty of chief scientific officer (CSO) for breast cancer research program at UTSW cancer center.

Members' Research Highlights (Cont'd)

Dr. Taosheng Chen at St. Jude Children's Research Hospital uses chemical biology approaches to inhibit PXR, a nuclear receptor promiscuously activated by many drugs to decrease drug efficacy and increase drug toxicity. His lab discovered that ligand-induced binding pocket expansion increases ligand-binding potential of PXR but with reduced affinity; therefore, drug candidates can be engineered to expand PXR's ligand-binding pocket and reduce their safety liability due to PXR binding (***PNAS***: https://www.pnas.org/doi/10.1073/pnas.2217804120?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed). They also designed PXR antagonists and described their mechanisms of action, showing that antagonist-induced PXR conformational changes are incompatible with transcriptional coactivator recruitment, thus providing additional approach to prevent PXR activation (***Nature Communications***: https://www.nature.com/articles/s41467-024-48472-1)

Dr. Yong Li at Baylor College of Medicine has developed monoclonal antibodies targeting a p53 mutant. The antibodies, in either IgG1 or dimeric IgA form, enhance T cell response in murine syngeneic tumor models. Tumor-infiltrating B cells and plasma cells (TIL-Bs) promote antitumor immunity in most cancers through cell- and antibody-based effector mechanisms. The IgG1 and dimeric IgA antibodies represent the effectors from TIL-Bs, albeit engineered, optimized, and amplified for maximum potency and minimal autoimmune responses by not targeting wild-type p53. This study was published in ***Journal of Hematology & Oncology***: https://jhoonline.biomedcentral.com/articles/10.1186/s13045-024-01566-1

Dr. Huiping Liu at Northwestern University Feinberg School of Medicine was awarded an elected member of American Society for Clinical Investigation (**ASCI**) in 2023 and **Chan Zuckerberg** Biohub Chicago Investigator in 2024. Her lab discovered that chemotherapy-evasive circulating tumor cell (CTC) clusters with stem cell properties are relatively quiescent with a specific loss of terminal sugar residues α2,6-sialic acids in glycoproteins due to decreased sialyl-transferase ST6GAL1, promoting adhesion proteins and stemness drivers for metastatic seeding in breast cancer. Neutralizing antibodies against these clustering drivers inhibit CTC cluster formation and improve therapy response, thereby blocking lung metastasis in TNBC. This study was published as a research article in ***Cancer Discovery*** **2023** (https://doi.org/10.1158/2159-8290.CD-22-0644).

Dr. Xiaoling Li and her team at NIEHS of NIH discovered that methionine restriction impairs T cell antitumor immunity in immunocompetent mice, and further showed that reduced gut microbial production of hydrogen sulfide partially underlies this defect. This study was published alongside a News & Views article in ***Nature Metabolism*** (https://www.nature.com/articles/s42255-023-00854-3). In a recent invited review in ***Trends in Endocrinology & Metabolism,*** they discussed how tumor stage-specific methionine dependence of immune cells and cancer cells in the tumor microenvironment could ultimately dictate the response of tumors to methionine restriction (https://www.cell.com/trends/endocrinology-metabolism/fulltext/S1043-2760(24)00023-7).

Members' Research Highlights (Cont'd)

Dr. Gloria Su, while at Columbia University, discovered that loss of Acvr1b in the presence of the Kras oncogene promotes the development of large and small precancerous lesions from both ductal and acinar cells. The study shows that it is possible for acinar cells to contribute to intraductal papillary mucinous neoplasm (IPMN), but the applicability of these observations to human IPMN should be further interrogated in future studies. This study was published in ***CMGH*** Acvr1b Loss Increases Formation of Pancreatic Precancerous Lesions From Acinar and Ductal Cells of Origin - ClinicalKey

Dr. Boyi Gan at MD Anderson Cancer Center published several papers focusing on cell death mechanisms in cancer therapy. His lab showed that BRCA1 deficiency induces a ferroptosis vulnerability to PARP and GPX4 co-inhibition and informed a therapeutic strategy for overcoming PARPi resistance in BRCA1-deficient cancers (***Cancer Discovery***, 2024; https://aacrjournals.org/cancerdiscovery/article/14/8/1476/746513/BRCA1-Mediated-Dual-Regulation-of-Ferroptosis), and demonstrated a multifaceted role of complex I in regulating ferroptosis and proposed a ferroptosis-inducing therapeutic strategy for LKB1-deficient cancers (***Molecular Cell***, 2024; https://www.sciencedirect.com/science/article/pii/S1097276524003241?via%3Dihub). In a recent review, they discussed the role of ferroptosis in cancer (***Cancer Cell***, 2024; https://www.sciencedirect.com/science/article/pii/S1535610824000965?via%3Dihub). They also discovered a new form of cell death termed disulfidptosis, which refers to cell death induced by disulfide stress. Their findings reveal that the susceptibility of the actin cytoskeleton to disulfide stress mediates disulfidptosis and suggest a therapeutic strategy to target disulfidptosis in cancer treatment (***Nature Cell Biology***, 2023; https://www.nature.com/articles/s41556-023-01091-2). Dr. Gan recently was also selected as a member of 2023 American Association for the Advancement of Science (AAAS) Fellows.

Dr. Li Ma at The University of Texas MD Anderson Cancer Center was elected as a 2023 **American Association for the Advancement of Science (AAAS) Fellow** for her fundamental discoveries of cancer spread and resistance to treatment, including pioneering work on the role of long and short non-coding RNAs in metastasis. In 2024, she reported that the lncRNA MALAT1 protects against osteoporosis and bone metastasis, which revealed the fundamental roles of MALAT1 in physiological and pathological processes and suggested that MALAT1's functional effector, TEAD, could be a new target against osteoporosis and bone metastasis. This study was published in ***Nature Communications*** (https://www.nature.com/articles/s41467-024-46602-3). Moreover, she discovered that the liver tumor suppressor LIFR regulates cholesterol-driven bidirectional hepatocyte-neutrophil crosstalk to promote liver injury repair and regeneration. This study was published in ***Nature Metabolism***(https://www.nature.com/articles/s42255-024-01110-y).

Dr. Xiao Song in **Dr. Shi-Yuan Cheng**'s laboratory at Northwestern University discovered that mutation-driven RNA alternative splicing impacts glioma developmental hierarchies and malignancy. Furthermore, they demonstrated that targeting tumor-promoting isoforms and upstream splicing factors could be a promising approach for glioma therapy. This study was published in the ***Journal of Clinical Investigation***: https://www.jci.org/articles/view/173789.

Members' Research Highlights (Cont'd)

Dr. Zhenkun Lou at Mayo Clinic identified a new ATPase, SLFN5, that promotes high order chromatin domain formation to regulate the DNA double strand break repair pathway choice and safeguard genome stability. ***Molecular Cell*** 2023, (https://www.cell.com/molecular-cell/fulltext/S1097-2765(23)00083-7?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1097276523000837%3Fshowall%3Dtrue. In addition, Dr. Lou found the RNA-binding protein HnRNPA2/B1 is a endogenous inhibitor of RPA and acts as a switch in regulating ATR activation and replication stress response ***Molecular Cell*** 2023, https://www.cell.com/molecular-cell/fulltext/S1097-2765(23)00003-5?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1097276523000035%3Fshowall%3Dtrue).

Dr. Erxi Wu at Baylor Scott & White Health (BSWH) and Baylor College of Medicine (BCM) and the Hu lab at Hunan University identified a non-G-quadruplex DNA aptamer targeting nucleolin for bladder cancer diagnosis and therapy. This study was published as a frontispiece cover article in ***Advanced Healthcare Materials***: https://onlinelibrary.wiley.com/doi/10.1002/adhm.202300791. Dr. Wu and the Huang lab at BSWH and BCM investigated the distinct roles of astrocytes in sensory transmission during different sleep and wake states in mice. This study was published in ***Nature Communications***: https://www.nature.com/articles/s41467-023-37974-z. Dr. Wu collaborated with the Yi lab at UT Austin to develop a deep learning method, AD-Syn-Net, for identifying mutations and co-mutations associated with Alzheimer's disease. This report was published in ***Briefings in Bioinformatics***: https://academic.oup.com/bib/article/24/2/bbad030/7031152. Dr. Wu identified a novel approach for blood-based marker identification in glioblastoma using whole blood globin reduction and comprehensive analysis. The article was published in ***npj Genomic Medicine***: https://www.nature.com/articles/s41525-022-00348-3.

Dr. Qing Richard Lu from Cincinnati Children's Hospital and University of Cincinnati published several papers. In one of studies, his lab identifies epigenetic silencing as a barrier to remyelination in multiple sclerosis (MS) and demonstrates that a small-molecule inhibitor, ESI1, reversing age-related cognitive decline through metabolic reprogramming and chromatin remodeling (***Cell***. 2024; 187:2465-2484.e22; https://pubmed.ncbi.nlm.nih.gov/38701782/). In another study, his lab shows that CTDNEP1 mutations drive MYC amplification, chromosomal instability, and poor prognosis in MYC-driven medulloblastomas, acting as a tumor suppressor by regulating MYC activity and mitotic fidelity, with co-targeting of MYC and CHEK1 offering a potential therapeutic strategy (***Nature Commun***. 2023. https://pubmed.ncbi.nlm.nih.gov/36765089/). His lab also shows that Liquid-liquid phase separation, rather than nuclear localization, of YAP fusion proteins drives ependymoma tumorigenesis by forming nuclear condensates that concentrate transcriptional co-activators, promote oncogenic programs, and present a potential therapeutic target for YAP-fusion-induced cancers (***Nature Cell Biology***. 2023; 25:323-336. https://pubmed.ncbi.nlm.nih.gov/36732631/)

Dr. Yejing Ge and her team at the MD Anderson Cancer Center discovered that the suppression of endogenous retroviruses (ERVs, a type of transposons) is an essential pathway to protect adult stem cells in the skin. In their murine model, they observed viral like particles originated from the ERVs, accompanied by hair loss and stem cell exhaustion, which can be rescued by antiviral drugs. Implications are behind these findings include how innate antiviral pathways can be leveraged to expose cancer vulnerability. This study is recently published in ***Cell*** https://www.cell.com/cell/fulltext/S0092-8674(24)01155-3

Genes & Diseases

eISSN 2352-3042 pISSN 2352-4820 CN 50-1221/R

Genes & Diseases is a international journal for molecular and translational medicine.

Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis will be placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.

IF: 6.9

Biochemistry & Molecular Biology: Q1 (36/313)

Genetics & Heredity: Q1(16/191)

期刊微信公众号 编辑微信 融媒体官网 期刊微信视频号

Homepage: www.sciencedirect.com/journal/genes-and-diseases
Email: editor@genesndiseases.com

KeAi

Genes & Diseases

An international journal for molecular and translational medicine

Journal Metrics

SNIP: 1.74 (2023)
CiteScore: 9.5 (2023)
Impact Factor: 6.9 (2024)
SCImago Journal Rank (SJR): 1.446 (2023)

Editors-in-Chief

Ailong Huang and Tong-Chuan He

Deputy Editors-in-Chief

Zhenghe John Wang and Xiaodong Zhao

Published Quarterly
Open Access
ISSN: 2352-3042

Types of Articles

Full length article, review article, short communication, correspondence, perspective, commentary, views on news, and research watch.

Review Speed



Call for Papers

Email: editor@genesndiseases.com
Home page: https://www.journals.elsevier.com/genes-and-diseases/
Journal page: https://www.sciencedirect.com/journal/genes-and-diseases

In partnership with ACACR

POSITION ANNOUNCEMENT
Tenure-track faculty
Assistant or Associate Professor
COLLEGE OF PHARMACY
UNIVERSITY OF GEORGIA

Position Summary:

The Department of Pharmaceutical and Biomedical Sciences in the College of Pharmacy at the University of Georgia invites applications for a full-time tenure track position at the level of Assistant or Associate Professor. We seek an individual who will build and maintain a strong extramurally-funded research program in the area of drug discovery, ideally with emphasis on the application of computer-aided drug design methods including AI. The successful candidate will build on existing research strengths in the department, which include medicinal chemistry and chemical biology and will be committed to excellence in teaching at the undergraduate and graduate levels in the College of Pharmacy. The position includes a competitive salary, excellent laboratory space, and a generous start-up package.

Applicants must hold a PhD or equivalent degree in the appropriate field, have at least two years of postdoctoral training, and have a strong publication record.

Application Instructions

Applications must be submitted through the UGA Jobs website at https://www.ugajobsearch.com/postings/400994. Application materials submitted in other ways will not be accepted. For full consideration, please apply by December 1, 2024. Review of applications will begin on December 2, 2024, and continue until the position is filled. A complete application includes:

Cover Letter

Curriculum vitae

Two-page research statement

One-page statement of teaching philosophy

Three confidential letters of recommendation.

Please direct inquiries to the search committee chair, Professor David Crich, Georgia Research Alliance Eminent Scholar in Drug Design, Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia (David.Crich@uga.edu).

EEO Statement

The University of Georgia is an Equal Opportunity/Affirmative Action employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, ethnicity, age, genetic information, disability, gender identity, sexual orientation, or protected veteran status. Persons needing accommodations or assistance with the accessibility of materials related to this search are encouraged to contact Central HR

EINSTEIN CELL BIOLOGY

EINSTEIN
Albert Einstein College of Medicine

POSTDOCTORAL POSITION

Laboratory of Dr. B. Hilda Ye, PhD
Albert Einstein College of Medicine, Bronx, NY

A POSTDOCTORAL FELLOWSHIP is available immediately to study the molecular and cellular mechanisms of HTLV-I driven adult T-cell leukemia/lymphoma (ATLL). Being the only human cancer caused by a retrovirus, ATLL is a fatal disease with no effective therapy. ATLL is distinguished from other types of T cell lymphomas in its unique genetic and phenotypic characteristics as well as clinical behavior. Evidence is also accumulating that ATLL diagnosed in North America and Japan may differ in their mutation patterns and anti-HTLV-I host immune response. We use patient samples as well as cell line and PDX models to investigate the roles played by epigenetic dysregulation, altered crosstalk of cell signaling pathways, elevated replication stress in ATLL development, and interactions between transformed ATLL T cells and host immunity. More information about our work can be found at: https://www.einsteinmed.edu/faculty/7901/b-hilda-ye/

Recent PhD or MD graduates with significant research experience are preferred. Proficiency in molecular biology techniques including the manipulation and analysis of gene expression in cultured and primary cells is required. Some knowledge of immunology would be desirable, so are computational skills. First authored publication(s) in peer-reviewed, English language journals are necessary. Ability to work independently, motivation to make new discoveries and a strong work ethic are important. A curriculum vitae with a description of research experiences and contact information for three references should be sent to hilda.ye@einsteinmed.edu. Please make the email subject "Postdoctoral Application - Your name."

The Albert Einstein College of Medicine (Einstein) is one of the nation's premier institutions for basic research and clinical investigation with more than 300 research laboratories funded by more than $220 million from the National Institutes of Health. There are ~200 PhD students and ~250 postdoctoral fellows at Einstein https://www.einsteinmed.edu/about/ . The Department of Cell Biology is an intellectually diverse and highly interactive research community. We have a proud history of launching the careers of many talented young scientists https://www.einsteinmed.edu/departments/cell-biology/

THE UNIVERSITY of WISCONSIN MADISON

Dr. Ting Fu's lab at the UW-Madison School of Pharmacy is seeking **postdoctoral researchers and Ph.D. students**. The lab focuses on the role of bile acids and nuclear receptors (FXR) in intestinal physiology, metabolism, inflammation, cancer, and gut microbiome interactions. Using advanced techniques such as pharmacological tools, gene knockout mice, 3D organoids, mucosal immunology, and microbiome sequencing, the lab aims to identify novel diagnostic biomarkers and develop small-molecule compounds targeting cancer metabolism and immunomodulation. Dr. Fu completed her Ph.D. at UIUC under Prof. Jongsook Kim Kemper and her postdoctoral research at the Salk Institute with Prof. Ronald Evans. Her work has been published in high-impact journals including *Nature, Cell, PNAS*. For more information, please visit the PI's webpage. https://apps.pharmacy.wisc.edu/sopdir/ting_fu/

Open Positions:

1. **Postdoctoral Researchers**: Candidates with a Ph.D. in molecular biology, cell biology, immunology, physiology, nutrition, or microbiology are encouraged to apply. Strong communication skills, a collaborative spirit, and relevant research experience are preferred.

Ph.D. Students: Students with a background in life sciences and research experience are welcome to apply. Visit Ph.D. Admissions for more details.

1 How to Apply: Please send your Cover Letter and CV (combined into a single PDF) to **ting.fu@wisc.edu**, specifying the position of interest. The Cover Letter should outline your research experiences and skillsets.

2 Successful candidates will receive competitive salaries and benefits. We look forward to your application!

Selected publication:

1. Xingchen Dong, Fei Sun, …, Ting Fu. The dichotomous roles of microbial modified bile acids, 7-oxo-Deoxycholic Acid and Iso-Deoxycholic Acid in intestinal tumorigenesis (under publication in PNAS).
2. Xingchen Dong, Chunmiao Cai, Yu Zhu, …Wei Xu, Paul Marker, Ting Fu. FXR mediates macrophage-intrinsic responses to suppress colitis-induced colon cancer progression. Jan 2024, JCI Insight.
3. Ting Fu*, Tao Huan*, Gibraan Rahman*, Hui Zhi, …, Manuela Raffatellu, Pieter C. Dorrestein, Michael Downes, Rob Knight*, Ronald M. Evans*. Paired microbiome and metabolome analyses associate bile acid changes with colorectal cancer progression. 2023 Aug, Cell Reports.
4. Ting Fu, Yuwenbin Li, Tae Gyu Oh, Fritz Cayabyab, ...,Ye Zheng, Christopher Liddle, Michael Downes*, Ronald M. Evans*, et al. FXR mediates ILC-intrinsic responses to intestinal inflammation. Dec 12, 2022, PNAS.
5. Robert A. Quinn, Alexey V. Melnik, Alison Vrbanac, Ting Fu, …Ronald M. Evans, Victor Nizet, Rob Knight, and Pieter C. Dorrestein, et al. Global Chemical Impacts of the Microbiome Include Unique Bile Acid Conjugates that Stimulate FXR. Nature, 2020 Mar; 579(7797):123-129.
6. Ting Fu, Sally Coulter, Eiji Yoshihara, Tae Gyu Oh, …,Michael Downes*, Ronald M. Evans*, et al. FXR regulates intestinal stem cell proliferation. FEBRUARY 21, 2019, Cell.
Sunmi Seok*, Ting Fu*, Sung-E Choi, Yang Li, …Jian Ma, Byron Kemper, and Jongsook Kim Kemper. Transcriptional regulation of autophagy by an FXR/CREB1 axis. 04 December 2014, Nature
7. Ting Fu, SungE Choi, …,Jongsook Kim Kemper. Aberrantly elevated miR-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor β-Klotho. PNAS, 2012 Oct 2.
https://scholar.google.com/citations?user=Xgj_zLsAAAAJ&hl=en

Selected Award and Funding:

2024-2030 NCI MERIT Award (R37)
2024 Faculty Starter Grant Award, PhRMA Foundation
2024-2025 Early stage Investigator Award, Margaret Q. Landenberger Research Foundation
2023-2027 Research Scholar Grant, American Cancer Society (ACS) – Coaches vs. Cancer – Bo Ryan-Jay Holliday Families Fund

THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center
Making Cancer History®

Postdoctoral fellow positions are available in the Ge Lab, Department of Cancer Biology, MD Anderson Cancer Center, Houston, TX. Research in the Ge lab applies principles of development biology, and mouse genetics tools to explore molecular mechanisms underlying stem cell plasticity, and how its deregulation causes human diseases, including wound repair, cancer, and aging. Examples for our conceptual and technological approaches can be found in our recent work on skin retrotransposons published in ***Cell***. Please visit the Ge Lab website for additional information: http://yejinggelab.com. For those interested in joining us, please send your Cover Letter briefly describing your background and research interest, Curriculum Vitae to yejinggelab@gmail.com. Additionally, please arrange to have three reference letters submitted to the same address on your behalf.

Association of Chinese Americans in Cancer Research

SCAN me to join the ACACR

2024 Annual Seminar Series

The seminar series was organized by Drs. Erxi Wu (Baylor College of Medicine) and Wei Xu (UW-Madison).
The seminars took place from 3:00 to 4:30 pm Eastern Time (12:00 to 1:30 pm Pacific Time) on the indicated Fridays, and featured two speakers each time, typically one junior and one senior Principal Investigator (PI). Each talk included a 35-minute presentation followed by a 10-minute Q&A session. To accommodate the travel plans of many ACACR members attending the upcoming 19th SCBA/14th CBIS International Symposium in Guiyang, we did not hold seminars on 7/19, 7/26, and 8/2.

Date	Presenter 1	Presenter 2
6/21/24	Wenwei Hu, Ph.D. Professor at Rutgers University	Pingping Hou, Ph.D. Assistant Professor at Rutgers University
	The alteration of hepatic PPARa and lipid metabolism in cancer cachexia	Unveiling Mechanistic Insights into Cell Plasticity-Driven Resistance to KRAS-Targeted Therapy in Pancreatic Cancer
6/28/24	Richard Bingcheng Wang, Ph.D. Prof and Chair at Case Western Reserve	Dechen Lin, Ph.D. Assistant professor at USC
	Time-Resolved Live Cell Spectroscopy Reveals Multimeric Assembly of EphA2 Kinase Underlying Its Dual Roles in Oncogenesis	Organoid modeling cancer evolution and biology
7/5/24	Donna Zhang, Ph.D. Professor at UF Scripps	Huadong Pei, Ph.D. Associate Professor
	Unraveling the intricacies of NRF2 in Cancer	The role of Histidine phosphorylation in Cancer
7/12/24	Rong Li, Ph.D. Prof and Chair at George Washing University	Tao Wu, Ph.D. Assistant Professor at BCM
	R-Loop Dynamics and Function In BRCA1-Related Tumorigenesis	Uncover the Dynamic Driving Forces Underpinning Cellular Plasticity Unlocking
8/9/24	Qing Richard Lu, Ph.D. Prof and Chair at Cincinnati Children's	Ting Fu Assistant Professor at UW-Madison
	Decoding Brain Cancer: from Developmental Origins to Targeted Therapies	The dichotomous roles of microbial modified bile acids, 7-oxo-DCA and Iso-DCA in intestinal tumorigenesis
8/16/24	Jun Wang, Ph.D. Assistant Professor at NYU	Liling Wan, Ph.D. Assistant Professor at UPenn
	Probing novel immune feedback modulators for immunotherapy of cancer and beyond	Transcriptional Condensates in Cell Fate Control and Cancer
8/23/24	Hong Wen, Ph.D. Professor at Van Andel Institute	Chong Wu, Ph.D. Assistant professor at UT MD Anderson
	The histone acetylation reader ENL in cancer	Large-scale imputation models for multi-ancestry proteome-wide association analysis
8/30/24	Qianben Wang, Ph.D. Professor at Duke Cancer Institute	Ruli Gao, Ph.D. Assistant Professor at Northwestern
	Integrated CRISPR/Cas13-Based RNA Editing and Nanotechnology for Targeting 'Undruggable' Transcriptional and Post-Transcriptional Vulnerabilities in Lethal Prostate Cancer	Integrative reconstruction of genetic evolutionary lineages and cell fate transition trajectories with long read single cell RNA sequencing

Election of ACACR Officers

9/26/2024 Announcement of the election
Dear Colleagues,

We are currently accepting nominations for the next president of the Association of Chinese Americans in Cancer Research (ACACR). The new president will begin his/her term in 2026, serving as president-elect from 2024 to 2026 as a member of the ACACR executive team and participating in the organization of ACACR activities.

We welcome both nominations and self-nominations from ACACR members. Please send the nominee's CV to me at bgan@mdanderson.org. The deadline for nominations is October 16, three weeks from now.

Thank you!

Boyi

10/24/2024 Announcement of the candidates
Dear friends and colleagues,

In response to the solicitation from the ACACR community, we are pleased to present two outstanding candidates for the position of President-Elect: Dr. Erxi Wu from Baylor College of Medicine and Dr. Wei Xu from the University of Wisconsin-Madison. Their CVs are attached below.

We are now opening the voting process. Please use the following link to select your preferred candidate (and kindly vote only once). Voting will remain open for one week, ending at 8 PM EST on October 31. Over the next week, I will send periodic reminder messages to the group.

Thank you!

Boyi

10/31/2024 Announcement of the election results
Dear friends and colleagues,

Thank you for your active participation in voting for the ACACR President-Elect. We received over 360 votes this time. I am thrilled to announce that, for the first time in our society's history, we will have a female President. Many congratulations to Dr. Wei Xu on being selected as the President-Elect! I would also like to thank Dr. Erxi Wu for his candidacy and continued dedication to the society.

Best regards,

Boyi

How to become a member of ACACR 如何成为ACACR 协会会员

感谢大家对ACACR 的关心和鼓励，更感谢许多志愿者们的付出。我们的财务李勇已把协会的银行帐户，PayPal 帐户开好；我们 IT 小组的戴木水已经将网上自动付款体系建成。下面是如何成为我们协会成员了。

我们有两种会员制，普通会员（regular member) 和 临时会员（associate member)。普通会员又分终生会员（lifetime membership) 以及年度会员，前者会费 $500, 后者会费每两年$100。临时会员暂不收费，但以后可能会有所改变。

目前我们还是半自动化注册（即有部分是手工）。请到我们网站 acacr.org 在"membership"栏下载注册表，填好后电邮给表最后的邮件地址。

我们共有三种付会员费的方式：

1. 在我们网站上用Paypal(或信用产卡）付tacacr@outlook.com
2. 银行直接Transfer Money (Zelle, like Chase Quickpay) to tacacr@outlook.com.
3. 支票. 请写明付给 ″Association of Chinese Americans in Cancer Research, Inc." 需要邮寄支票的，请与Dr. Lanjing Zhang 联系，lanjing.zhang@rutgers.edu，请在电邮上注明 ACACR member.

我们将在收到付款后五-七个工作日发出收据。

协会会员的益处：

协会普通会员和临时会员都可以参加WeChat 的讨论，信息交流，年会以及其他一些由ACACR 组织的活动。普通会员还有以下一些额外的福利。

（1）协会内部选举和被选举权；
（2）由ACACR 推荐去AACR 各种委员会和杂志编辑部；
(3）在我们协会网站上招人广告栏上发广告（微信群里的帖子会很快被淹没）；
（4）在我们协会网站上贴一些会议通知；
（5）在我们协会每月一次的 Newsletter 上登广告（非会员收费 $20);
（6）我们协会网站和 Newsletter "Research Highlights" 栏目中将优先选发协会会员刚发表的文章；
（7）今后ACACR 有小型奖励机会（award opportunity), 将优先考虑我们的普通会员；
(8) 今后购买ACACR 赞助商的物品时可能有折扣机会。

普通会员今后可能有的福利还包括会员学术交流活动（annual retreat), 成员互助等。

Association of Chinese Americans in Cancer Research

SCAN me to join the ACACR

ASSOCIATOIN OF CHINESE AMERICANS IN CANCER RESEARCH

PO Box 1382,
Timonium, MD 21093

Phone: (443) 923-9498
Email: acacr@weebly.com

We are on the web
http://www.acacr.org/

Our Missions

Our mission is to prevent and cure cancer through fostering interactions and collaborations among Chinese Americans in all areas of cancer research including cancer biology, etiology, genetics, epidemiology, prevention, diagnosis, and treatment. ACACR also promotes interactions and collaborations among professionals of Chinese background and/or ethnicity in cancer research through the exchange of information in education, technology, employment, and business opportunities.

Wish You Happy Holidays!

Management team (web link)

Board of Directors
Shiyuan Cheng, PhD
Wei Gu, PhD
Yibin Kang, PhD
Jinsong Liu, MD, MA, PhD
Hua Lu, MD, PhD
Shaomeng Wang, PhD

President (2023-2024)
Gen-Sheng Feng, PhD

President (2024-2026)
Boyi Gan, PhD

General Secretary
Erxi Wu, PhD

Treasurer
Lanjing Zhang, MD

Committee chair/co-chair

Annual meeting
Gen-Sheng Feng, PhD
Tongchuan He, MD, PhD
Binhua Zhou, MD, PhD

Audit
Zhaohui Feng, PhD

Fundraising
Bin Li, MD
Xing Fan, MD PhD

IT-support
Wenwei Hu, PhD
Mushui Dai, MD, PhD

Membership
Yaguang Xi, MD, PhD, MBA

Newsletters
Lanjing Zhang, MD
Wei Xu, PhD
Ting Fu, PhD

Past Presidents
2021-2022
Lin Zhang, PhD

2019-2020
Zhenkun Lou, PhD

2017-2018
Shiyuan Cheng, PhD

Sponsors